AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.

Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising lipid-lowering therapies in patients with acute coronary syndrome (ACS).

The ZODIAC (NCT05844566) trial aimed to compare a DSS aligned with the 2019 ESC/EAS guidelines in addition to routine care with routine care alone in patients with ACS. The study aimed to assess whether the availability of a DSS resulted in early initiation of combination lipid-lowering therapies or the intensification of existing lipid-lowering therapy regimes over a 24-week period after an ACS event. An estimated 1,584 participants consented to randomized clinical trial sites to collect their data, where clinical sites were randomized to either standard of care or access to the DSS.

Recorded remotely from London, UK and Hamilton, CA, 2024.

Editors: Jordan Rance and Yazmin Sadik
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.